Specialized Pro-Resolving Mediator (SPM) pathway

The specialized pro-resolving mediator (SPM) pathway is a network of enzymatic biosynthetic routes that convert polyunsaturated fatty acid (PUFA) precursors — principally arachidonic acid (AA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) — into four structurally distinct families of lipid mediators that actively terminate the inflammatory response and restore tissue homeostasis. Unlike classical anti-inflammatory drugs that suppress the initiation of inflammation, SPMs operate during the resolution phase, promoting neutrophil clearance (efferocytosis), macrophage phenotype switching, and pro-resolving transcriptional programs.

In aging, the chronic, low-grade sterile inflammation called inflammaging is mechanistically linked to resolution failure — an inability to extinguish the inflammatory response after the inciting stimulus has cleared. SPM levels decline with age in multiple cohort studies, and deficient SPM tone is proposed as a proximal driver of age-related inflammatory pathology including Alzheimer’s disease, atherosclerosis, and sarcopenia ¹ ².

The SPM pathway intersects with this wiki’s fpr2 page (R35-Stage2), which describes biased agonism at the ALX/FPR2 receptor — the shared receptor for lipoxin A4 and resolvin D1 and a key mechanistic node for resolution signaling.

Druggability note (aging context)

druggability-tier: 2 — High-quality pharmacological probes exist (stable SPM analogs including RX-10045, a lipoxin A4 analog, reached Phase 3 for dry eye); no SPM-class drug is FDA-approved for any aging indication. Multiple analogs are in active clinical development for inflammatory diseases. The tier reflects the aging context rather than maximum druggability across all indications.

Four SPM families

The four classes differ by PUFA precursor, key biosynthetic enzymes, and receptor targets:

Family	Precursor	Key enzymes	Key members	Primary receptors	Key function
Lipoxins	Arachidonic acid (AA, n-6)	15-LOX (ALOX15) → 5-LOX (ALOX5); or aspirin-acetylated COX-2 (→ 15-epi-LXA4)	LXA4, LXB4, 15-epi-LXA4 (aspirin-triggered)	ALX/FPR2 (fpr2)	Halt neutrophil recruitment; first SPM family described (Serhan 1984)
E-series resolvins	EPA (n-3)	COX-2 (aspirin-acetylated) → 5-LOX; or cytochrome P450	RvE1, RvE2, RvE3	ChemR23 (chemr23), BLT1	Reduce neutrophil tissue entry; anti-nociceptive
D-series resolvins	DHA (n-3)	15-LOX (ALOX15) → 5-LOX (ALOX5)	RvD1, RvD2, RvD3, RvD4, RvD5, RvD6; aspirin-triggered AT-RvD series	GPR32 (gpr32), ALX/FPR2 (fpr2)	Promote macrophage efferocytosis; regulate NLRP3 inflammasome
Protectins	DHA (n-3)	15-LOX (ALOX15)	PD1/NPD1 (neuroprotectin D1), PDX	Not fully characterized; some FPR2 interaction	Neuroprotective; epithelial barrier repair
Maresins	DHA (n-3)	12-LOX (ALOX12)	MaR1, MaR2	LGR6 (MaR1); GPR18 (RvD2)	Tissue repair; regeneration program activation

Note on protectin receptors: PD1/NPD1 receptor identity is incompletely resolved; candidate receptors have been described but not yet confirmed as specific, high-affinity cognate pairs. no-mechanism

Biosynthetic routes

Lipoxins (from AA)

Arachidonic acid released from membrane phospholipids by phospholipase A2 is oxygenated in two sequential lipoxygenase reactions:

Transcellular synthesis (classic route): Leukocyte 5-LOX produces 5-HPETE → leukotriene A4 (LTA4); LTA4 is transferred to epithelial or platelet 12-LOX or 15-LOX to yield lipoxin A4 (LXA4) or B4 (LXB4).
Single-cell 15-LOX route: 15-LOX converts AA to 15-HpETE → 15-HETE; 5-LOX then generates LXA4.
Aspirin-triggered route (15-epi-LXA4): Aspirin-acetylated COX-2 produces 15R-HETE from AA; 5-LOX converts this to 15-epi-LXA4 (aspirin-triggered lipoxin, ATL). 15-epi-LXA4 has equivalent FPR2 potency to LXA4 — a key mechanistic explanation for aspirin’s anti-inflammatory benefit beyond COX inhibition ³.

E-series resolvins (from EPA)

EPA is oxygenated by aspirin-acetylated COX-2 to generate 18R-HEPE; 5-LOX then produces resolvin E1 (RvE1) and RvE2. Cytochrome P450-dependent routes generate additional E-series metabolites. RvE1 signals through ChemR23 (also called CMKLR1) on macrophages and dendritic cells ⁴.

D-series resolvins and protectins (from DHA)

DHA undergoes sequential 15-LOX (ALOX15) → 5-LOX (ALOX5) oxygenation to generate the D-series resolvins (RvD1–RvD6) and protectins. Aspirin-acetylated COX-2 generates the 17R-hydroxyl precursor, producing aspirin-triggered D-series (AT-RvD1 etc.). RvD1 signals through both GPR32 and ALX/FPR2; RvD2 signals through GPR18 ⁵.

Maresins (from DHA)

Maresins are produced from DHA via 12-LOX (ALOX12) in macrophages. MaR1 signals through LGR6; MaR2 biosynthesis and receptors are less characterized. Maresins are identified in resolving exudates, mouse infectious exudates, human macrophages, spleens, and plasma ⁶. The specific claim that maresins are enriched in bone marrow macrophages derives from Abdoulnour 2014 (doi:10.1073/pnas.1414005111; not locally verified). needs-replication

Receptor pharmacology and FPR2 biased agonism

The SPM pathway converges on a small set of GPCRs that mediate distinct resolution programs:

Receptor	Canonical SPM ligands	Competing ligands	Resolution output
ALX/FPR2 (fpr2)	LXA4, 15-epi-LXA4, RvD1, annexin A1	SAA, LL-37 (ll-37), fMLF	Neutrophil apoptosis; macrophage efferocytosis; NF-κB suppression
GPR32 (gpr32)	RvD1, AT-RvD1, RvD3, RvD5	—	Macrophage phagocytosis; bacterial clearance
ChemR23 (chemr23)	RvE1, RvE2	Chemerin (competing)	Dendritic cell resolution responses; macrophage phenotype switch
LGR6 (lgr6)	MaR1	—	Tissue regeneration; wound repair
GPR18	RvD2	—	Macrophage bone marrow egress; hepatic resolution

Biased agonism at FPR2: The ALX/FPR2 receptor is the most extensively characterized SPM receptor and exhibits archetypal biased agonism — see fpr2 for detailed mechanistic treatment. Briefly: lipoxin A4 and resolvin D1 stabilize a Gαi-coupled conformation that drives anti-inflammatory signaling (MAPK deactivation, PI3K-δ → Akt → NF-κB suppression); while LL-37 (ll-37) and serum amyloid A stabilize β-arrestin-biased conformations that drive pro-inflammatory outcomes. The relative abundance of pro-resolving vs. pro-inflammatory FPR2 ligands determines receptor bias tone, and this balance is disrupted in aging ¹.

Wang 2014 cross-reference: Hippocampal LXA4 protein is reduced in Alzheimer’s disease brains (correlation with MMSE r=0.475, p<0.0005); however, FPR2/ALX receptor protein level in AD was NOT significantly different by Western blot (z=−0.053, p=0.958) per Wang 2014. ChemR23, not FPR2, was elevated in AD hippocampus in that study. See fpr2 for the verified claim and appropriate qualification.

Role in aging and inflammaging

Resolution-failure hypothesis

Inflammaging — the chronic, low-grade sterile inflammation that accumulates across the lifespan — may result in part from progressive inability to terminate acute inflammatory responses rather than from increased inflammatory initiation alone. This resolution-failure framing reframes inflammaging as a deficit in active pro-resolving mediator production rather than simply excess pro-inflammatory mediator production ¹.

Supporting observations:

Multiple cohort studies report reduced circulating SPM levels in older compared to younger adults; the magnitude of decline is incompletely quantified and varies by mediator class and tissue. needs-replication — specific age-stratified measurements need verification in large prospective cohorts.
RvE1 levels are reduced and ChemR23 signaling is protective in an Angiotensin II–induced hypertensive mouse model ⁷. Whether circulating RvE1 is decreased in human hypertensive patients has not been confirmed in this source. needs-human-replication
LXA4 is reduced in hippocampal tissue from AD patients; the decline correlates with cognitive score (see fpr2).
DHA precursor availability — required for D-series resolvin and protectin biosynthesis — declines with age in some populations; dietary omega-3 supplementation can partially restore precursor flux.

Neurodegenerative disease connection

SPM deficiency is documented in neurodegenerative conditions with strong aging risk factors. PD1/NPD1 is produced in the brain from DHA and is neuroprotective in models of Alzheimer’s and Parkinson’s disease. Deficient SPM tone in the CNS is proposed to permit neuroinflammatory amplification that would otherwise be resolved ². needs-human-replication — most mechanistic data is from rodent models.

Efferocytosis and senescent-cell clearance

SPMs, particularly maresins and D-series resolvins, drive macrophage efferocytosis — the phagocytic clearance of apoptotic cells. Impaired efferocytosis in aging permits accumulation of secondary necrotic debris and downstream DAMP-driven sterile inflammation. The mechanistic link between SPM deficiency and impaired efferocytosis in aged tissue is an area of active investigation ⁸. needs-replication

Interaction with senescence and SASP

SASP-derived prostaglandin E2 (PGE2) competes with SPMs for COX-2-derived lipid precursors and biases macrophage arachidonate flux toward pro-inflammatory eicosanoids. This represents a mechanism by which the senescent cell burden of aging suppresses SPM biosynthesis — creating a feedforward loop between senescent burden and resolution failure. no-mechanism — direct mechanistic evidence for SASP-driven SPM suppression in aged tissues is limited.

Cross-pathway interaction with the 15-PGDH gerozyme axis

The Blau/Bhutani lab’s 15-pgdh gerozyme story (Palla 2021 muscle, Bakooshli 2023 NMJ, Singla 2025 cartilage) operates on the opposite arm of the same prostaglandin-flux network: pharmacological inhibition of 15-PGDH (with sw033291 or Epirium Bio derivatives) raises tissue PGE2 by blocking its catabolism — and is regenerative for aged muscle, NMJ, and articular cartilage. This creates a structural tension worth noting: the SPM-pathway frame views PGE2 as a pro-inflammatory eicosanoid that competes against resolution, while the gerozyme frame views age-elevated 15-PGDH activity as depleting a homeostatic PGE2 pool whose physiologic restoration is regenerative. The reconciliation is likely (a) tissue-context dependent (synovial macrophages vs satellite cells respond to PGE2 differently), (b) dose-dependent (physiologic vs SASP-supraphysiologic), and (c) receptor-subtype dependent (EP4 anabolic signaling in muscle vs broader prostanoid pathway in resolution). This unresolved cross-pathway dynamic is a key open question for any clinical program aiming to raise tissue PGE2. contradictory-evidence

Therapeutic landscape

SPM analogs

Native SPMs have short half-lives (minutes to hours) due to rapid metabolic inactivation. Stable chemical analogs are in clinical development:

Compound	Class	Clinical stage	Indication
RX-10045	Lipoxin A4 analog	Phase 3 (dry eye)	Dry eye disease; not yet tested in aging
ARI-3037MO	Resolvin E1 analog	Phase 2	Periodontal disease
Benzo-LXA4 analogs	Lipoxin A4 analogs	Preclinical	Various inflammatory models

No SPM analog has entered clinical trials for an aging indication as of 2026-05-09. needs-human-replication

Dietary precursor supplementation

Omega-3 fatty acid supplementation (EPA + DHA) provides biosynthetic precursors for E-series and D-series resolvins and for protectins and maresins. This is a mechanistic rationale for why omega-3 supplementation has pro-resolving effects that extend beyond simple competitive inhibition of AA-derived eicosanoids. The link between omega-3-metabolism and SPM biosynthesis is well-established biochemically but dose-response relationships for SPM production in aging humans are poorly characterized. dose-response-unclear

Aspirin as indirect SPM inducer

Low-dose aspirin’s aspirin-acetylated COX-2 generates 15-epi-LXA4 (aspirin-triggered lipoxin) and AT-RvD series with equivalent receptor potency to their native counterparts. This is proposed as a secondary mechanism for aspirin’s cardiovascular benefit beyond thromboxane suppression, though no aging trial has used SPM induction as a primary endpoint.

Canonical database entries

Database	ID	Entry
Reactome	R-HSA-9018678	Biosynthesis of specialized proresolving mediators (SPMs)
Reactome	R-HSA-9018676	Biosynthesis of D-series resolvins (lipoxygenase route)
Reactome	R-HSA-9020265	Biosynthesis of aspirin-triggered D-series resolvins
KEGG	hsa00590	Arachidonic acid metabolism (includes LXA4, LXB4; partial SPM coverage)
WikiPathways	WP5155	Arachidonic acid (AA) oxylipin metabolism (includes lipoxins and SPMs)

KEGG coverage gap: KEGG hsa00590 covers lipoxins but does not comprehensively represent EPA/DHA-derived SPMs (resolvins, protectins, maresins). Reactome R-HSA-9018678 is the more complete curated reference for the full four-family SPM pathway. needs-canonical-id — a dedicated KEGG map covering all four SPM families does not appear to exist; hsa00590 is the closest available entry.

Cross-references

fpr2 — ALX/FPR2 receptor; biased agonism; lipoxin A4 + RvD1 pro-resolving signaling vs. LL-37 / SAA pro-inflammatory signaling; Wang 2014 AD data with LXA4 and FPR2 claims verified
ll-37 — LL-37/cathelicidin competes with lipoxin A4 at FPR2; pro-inflammatory FPR2 bias
camp — CAMP gene; parent of LL-37; upstream of FPR2 ligand pool
chronic-inflammation — Hallmark; SPM deficiency as mechanistic driver of inflammaging
altered-intercellular-communication — Hallmark; SPM intercellular signaling across neutrophils, macrophages, epithelium
cellular-senescence — SASP/PGE2 competing with SPM biosynthetic flux (proposed mechanism)
15-pgdh — the prostaglandin-degrading gerozyme; antithetical arm of prostaglandin-flux regulation (PGDHi raises PGE2; SPMs compete with PGE2 — cross-pathway tension)
sw033291 — canonical 15-PGDH inhibitor; raises tissue PGE2 to physiologic levels
nlrp3-inflammasome — D-series resolvins (RvD2) downregulate NLRP3 activation; cross-pathway regulation
macrophage-efferocytosis — (implicit stub) Primary downstream effector of SPM activity
arachidonic-acid-pathway — (implicit stub) Upstream; AA substrate pool and competing COX/LOX routing
omega-3-metabolism — (implicit stub) Upstream; EPA + DHA precursor supply for E- and D-series SPMs
inflammation-resolution — (implicit stub) Downstream process coordinated by SPMs
gpr32 — (implicit stub) Resolvin D1/D2/D3 receptor
chemr23 — (implicit stub) Resolvin E1/E2 receptor
lgr6 — (implicit stub) Maresin 1 receptor
alox15 — (implicit stub) 15-lipoxygenase; key biosynthetic enzyme for lipoxins and D-series SPMs
alox5 — (implicit stub) 5-lipoxygenase; second step in lipoxin and D-series resolvin synthesis
alox12 — (implicit stub) 12-lipoxygenase; key enzyme for maresin biosynthesis

Limitations and gaps

Human cohort data is sparse. Most evidence for SPM decline with age comes from cross-sectional data or disease cohorts (AD, hypertension) rather than prospective aging cohorts with quantified circulating SPM levels. needs-replication
Receptor identity for protectins is incomplete. PD1/NPD1 lacks a confirmed specific cognate receptor, limiting receptor-targeted therapeutic design. no-mechanism
LGR6 as MaR1 receptor needs confirmation. The LGR6/MaR1 pairing has been proposed but requires additional replication. needs-replication
No SPM-class intervention in aging clinical trials. The field remains in the stable-analog development stage. needs-human-replication
SPM precursor supplementation dose-response. Optimal EPA/DHA supplementation to maximize SPM biosynthesis in aged individuals is undefined. dose-response-unclear
SASP–SPM competition mechanism. The proposed feedforward loop between SASP-derived PGE2 and reduced SPM biosynthesis is mechanistically plausible but not directly demonstrated in aged tissue. no-mechanism

Footnotes

doi:10.1016/j.smim.2018.09.002 · review · n=not applicable · Doyle R, Godson C · Semin Immunol 2018 · SPMs as agents of anti-ageing; age-related SPM decline; AD, atherosclerosis, obesity · local: not_oa (closed access); DOI verified via DOI lookup ↩ ↩² ↩³
doi:10.3389/fnagi.2022.780811 · review · n=not applicable · Ponce J et al. · Front Aging Neurosci 2022 · SPMs in Alzheimer’s and Parkinson’s disease; neuroinflammation resolution · local: verified (PDF downloaded) ↩ ↩²
doi:10.2174/187152806776383152 · review · n=not applicable · Romano M · Inflamm Allergy Drug Targets 2006 · lipoxins as promoters of inflammation resolution; aspirin-triggered 15-epi-LXA4 · local: not confirmed in archive ↩
doi:10.1016/j.mam.2017.03.005 · review · n=not applicable · Chiang N, Serhan CN · Mol Aspects Med 2017 · structural elucidation of SPMs and receptor pharmacology (GPR32, ChemR23, LGR6, ALX/FPR2) · local: not_oa (download failed) no-fulltext-access ↩
doi:10.1172/JCI97943 · review · n=not applicable · Serhan CN, Levy BD · J Clin Invest 2018 · resolvin, protectin, maresin families; quantitative resolution indices; immunoresolvent therapeutic framing · local: completed (PDF available) ↩
doi:10.3389/fimmu.2017.01400 · review · n=not applicable · Dalli J, Serhan CN · Front Immunol 2017 · SPM families (resolvins, protectins, maresins) in macrophage biology; microvesicle regulation of efferocytosis and SPM biosynthesis; maresin bioactive metabolome (MaR1, MaR2, MCTRs); tissue regeneration; identified in resolving exudates, mouse infectious exudates, human macrophages, spleens, plasma · local: verified (PDF downloaded) ↩
doi:10.1161/HYPERTENSIONAHA.123.21348 · in-vivo (mouse) · n=not specified · Zhang J et al. · Hypertension 2023 · RvE1/ChemR23 axis protects against hypertension and vascular remodeling in Angiotensin II–induced hypertensive mice; human patient data not confirmed from this source · local: not_oa (closed access) ↩
doi:10.1038/s41573-022-00470-y · review · n=not applicable · Mehrotra P, Ravichandran KS · Nat Rev Drug Discov 2022 · drugging efferocytosis; SPM pharmacology; macrophage clearance mechanisms · local: verified (PDF downloaded) ↩

🧬 Aging Wiki

Explorer

spm-pathway